Finder may earn compensation from partners, but editorial opinions are our own. Advertiser Disclosure

How to buy Gracell Biotechnologies stock | $10.42

Learn how to easily invest in Gracell Biotechnologies stock.

Gracell Biotechnologies Inc
NASDAQ: GRCL - USD
BIOTECHNOLOGY
$10.42
- $1.30 ( - 11.09%)

Gracell Biotechnologies Inc is a biotechnology business based in the US. Gracell Biotechnologies shares (GRCL) are listed on the NASDAQ and all prices are listed in US Dollars. Gracell Biotechnologies employs 202 staff and has a market cap (total outstanding shares value) of 0.00.

How to buy shares in Gracell Biotechnologies

  1. Compare share trading platforms.Use our comparison table to help you find a platform that fits you.
  2. Open your brokerage account. Complete an application with your details.
  3. Confirm your payment details. Fund your account.
  4. Research the stock. Find the stock by name or ticker symbol – GRCL – and research it before deciding if it's a good investment for you.
  5. Purchase now or later. Buy your desired number of shares with a market order or use a limit order to delay your purchase until the stock reaches a desired price.
  6. Check in on your investment. Optimize your portfolio by tracking your stock.

Gracell Biotechnologies stock price (NASDAQ: GRCL)

Use our graph to track the performance of GRCL stocks over time.

Gracell Biotechnologies shares at a glance

Information last updated 2021-10-23.
Latest market close$10.42
52-week range$9.75 - $33.70
50-day moving average $13.24
200-day moving average $12.66
Wall St. target price$34.67
PE ratio N/A
Dividend yield N/A (0%)
Earnings per share (TTM) $-1.36

Buy Gracell Biotechnologies shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.
Name Product Asset types Option trade fee Annual fee Signup bonus
Robinhood
Robinhood
Stocks, Options, ETFs, Cryptocurrency
$0
0%
Free stock (chosen randomly with a value anywhere between $2.50 and $200)
Sign up using the "go to site" link
Make unlimited commission-free trades in stocks, funds, and options with Robinhood Financial.
J.P. Morgan Self-Directed Investing
Stocks, Bonds, Options, Mutual funds, ETFs
$0 + $0.65/contract
0%
N/A
INVESTMENT AND INSURANCE PRODUCTS ARE: NOT A DEPOSIT • NOT FDIC INSURED • NO BANK GUARANTEE • MAY LOSE VALUE
Vanguard Personal Advisor
Stocks, Options, Mutual funds, ETFs
N/A
$20 per year
N/A
Financial advice powered by relationships, not commissions.
TradeStation
Stocks, Bonds, Options, Mutual funds, ETFs, Cryptocurrency
$0 + $0.50/contract
$0 per month
$50
Deposit qualifying assets of $5,000+
A platform built for all kinds of traders and all styles of trading
Sofi Invest
Stocks, ETFs, Cryptocurrency
N/A
0%
Get one free stock worth up to $1,000
Open an account
A free way to invest in stocks, ETFs and crypto.
Moomoo
Stocks
$0
$0 per year
Get a free stock valued up to $350
Open your Futu brokerage account via Moomoo
Trade stocks on the US, Hong Kong, Shanghai and Shenzhen markets.
loading

Compare up to 4 providers

*Signup bonus information updated weekly.

The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.

Is it a good time to buy Gracell Biotechnologies stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Gracell Biotechnologies price performance over time

Historical closes compared with the close of $10.42 from 2021-10-22

1 week (2021-10-18) -20.21%
1 month (2021-09-24) -23.38%
3 months (2021-07-23) -12.58%
6 months (2021-04-23) -19.10%
1 year (2020-10-21) N/A
2 years (2019-10-21) N/A
3 years (2018-10-21) N/A
5 years (2016-10-21) N/A

Gracell Biotechnologies financials

Gross profit TTM $0
Return on assets TTM -19.46%
Return on equity TTM -39.42%
Profit margin 0%
Book value $30.83
Market capitalisation $700.7 million

TTM: trailing 12 months

Shorting Gracell Biotechnologies shares

There are currently 1.1 million Gracell Biotechnologies shares held short by investors – that's known as Gracell Biotechnologies's "short interest". This figure is 3.6% down from 1.1 million last month.

There are a few different ways that this level of interest in shorting Gracell Biotechnologies shares can be evaluated.

Gracell Biotechnologies's "short interest ratio" (SIR)

Gracell Biotechnologies's "short interest ratio" (SIR) is the quantity of Gracell Biotechnologies shares currently shorted divided by the average quantity of Gracell Biotechnologies shares traded daily (recently around 53529.262335125). Gracell Biotechnologies's SIR currently stands at 20.47. In other words for every 100,000 Gracell Biotechnologies shares traded daily on the market, roughly 20470 shares are currently held short.

To gain some more context, you can compare Gracell Biotechnologies's short interest ratio against those of similar companies.

However Gracell Biotechnologies's short interest can also be evaluated against the total number of Gracell Biotechnologies shares, or, against the total number of tradable Gracell Biotechnologies shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Gracell Biotechnologies's short interest could be expressed as 0.02% of the outstanding shares (for every 100,000 Gracell Biotechnologies shares in existence, roughly 20 shares are currently held short) or 0.0274% of the tradable shares (for every 100,000 tradable Gracell Biotechnologies shares, roughly 27 shares are currently held short).

A SIR above 20% would generally be considered very high, pointing to a pessimistic outlook for the share price, with a discouraging number of investors currently willing to bet against Gracell Biotechnologies.

Find out more about how you can short Gracell Biotechnologies stock.

Gracell Biotechnologies share dividends

We're not expecting Gracell Biotechnologies to pay a dividend over the next 12 months.

You may also wish to consider:

Gracell Biotechnologies overview

Gracell Biotechnologies Inc. , a clinical-stage biopharmaceutical company, primarily discovers and develops cell therapies for the treatment of cancer in the People's Republic of China. Its lead product candidates include GC012F, a FasTCAR-enabled dual BCMA- and CD19-directed autologous CAR-T product candidate that is in Phase I trial for the treatment of multiple myeloma; GC019F, a FasTCAR-enabled CD19-directed autologous CAR-T product candidate, which is in Phase I clinical trial for the treatment of adult B cell acute lymphoblastic leukemia (B-ALL), as well as in preclinical stage for the treatment of relapsed or refractory (r/r) B cell non-Hodgkin's lymphoma (B-NHL); and GC027, a TruUCAR-enabled CD7-directed allogeneic CAR-T product candidate, which is in Phase I clinical trial for the treatment of adult T cell acute lymphoblastic leukemia. The company's product candidates also comprise; and GC007g, a donor-derived CD19-directed allogeneic CAR-T cell therapy that is in Phase I clinical trial for the treatment of r/r B-ALL. In addition, it has a portfolio of earlier stage product candidates targeting various cancer indications, such as ovarian cancer, breast cancer, peripheral T cell lymphoma, a subtype of NHL, and T cell lymphoblastic leukemia. The company was founded in 2017 and is headquartered in Suzhou, China. .

Frequently asked questions

What percentage of Gracell Biotechnologies is owned by institutions?
Currently 31.218% of Gracell Biotechnologies shares are held by institutions.
How many people work for Gracell Biotechnologies?
Latest data suggests 202 work at Gracell Biotechnologies.
When does the fiscal year end for Gracell Biotechnologies?
Gracell Biotechnologies's fiscal year ends in December.
Where is Gracell Biotechnologies based?
Gracell Biotechnologies's address is: Building 12, Block B, Suzhou, China, 215123
What is Gracell Biotechnologies's ISIN number?
Gracell Biotechnologies's international securities identification number is: US38406L1035

More guides on Finder

Ask an Expert

You are about to post a question on finder.com:

  • Do not enter personal information (eg. surname, phone number, bank details) as your question will be made public
  • finder.com is a financial comparison and information service, not a bank or product provider
  • We cannot provide you with personal advice or recommendations
  • Your answer might already be waiting – check previous questions below to see if yours has already been asked

Finder.com provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and finder.com Terms of Use.

Questions and responses on finder.com are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.
Go to site